Eli Lilly and Company (LLY.MX)
| Previous Close | 16,755.00 |
| Open | 16,470.00 |
| Bid | 16,050.02 x 100 |
| Ask | 16,799.99 x 10000 |
| Day's Range | 16,365.00 - 16,470.00 |
| 52 Week Range | 7,452.75 - 17,062.39 |
| Volume | |
| Avg. Volume | 249 |
| Market Cap | 14.735T |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 131.99 |
| EPS (TTM) | 123.99 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | 94.17 (0.56%) |
| Ex-Dividend Date | Aug 15, 2024 |
| 1y Target Est | N/A |
- Yahoo Finance Video
Eli Lilly history: Beyond the Ticker
With a rich history dating back to the 19th century, Eli Lilly (LLY) has faced struggles and successes. But a booming market cap has quickly turned it into the biggest pharmaceutical brand in the world. Let's dive into Lilly’s biggest moments with Beyond the Ticker. 1876 The company was founded by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran. Lilly served as the company president until he died in 1898. 1914-1918 Lilly experienced huge growth before and after World War I, including the expansion of its Indianapolis, Indiana, facility. 1923 The company began selling Iletin to treat diabetes, the world's first commercially available insulin product. 1952 Lilly became a publicly traded company on the New York Stock Exchange. 1971 Lilly acquired cosmetic manufacturer Elizabeth Arden for $38 million, eventually turning it into a financial success. 1987 Lilly sold Arden to Fabergé for $657 million. 2009 A fine of over $1.4 billion, the largest in US history, was imposed on Lilly for illegally marketing its best-selling mood disorder product Zyprexa. 2022 Lilly hit the jackpot with tirzepatide, a new type of GLP-1 product, sold as Mounjaro for type II diabetes. It began competing with Novo Nordisk’s (NVO) Ozempic, which had been on the market for a few years, but started struggling to meet demand as its popularity grew for off label weight loss use. 2023 Zepbound, the same formula as Mounjaro, was approved for obesity, and it began competing with Novo’s Wegovy. The two companies have a duopoly in this brand-new obesity market. The tirzepatide drugs have spiked Lilly’s stock by nearly 100% in the past year, and its annual revenue was over $34.1 billion in 2023 – a nearly 20% increase year-over-year. 2024 Lilly continues to reach all-time highs and is currently the biggest healthcare company in the world, with a market cap of well over $800 billion. Wall Street projects the GLP-1s alone will net Lilly $13 billion this year. And this is all before the FDA expands their use for other diseases. Its why Lilly is on track to make history and be the first trillion dollar healthcare company. From tech giants to retail titans, Beyond the Ticker is a historical series that takes a deep dive into some of Wall Street's trending companies and how they transformed into the financial icons they are today. Check out more of our Beyond the Ticker series, and be sure to tune in to Yahoo Finance. Editor's note: This video was produced by Zach Faulds.
Investor's Business DailyNovo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices
Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.
BloombergNovo, Lilly Slip as Biden Urges Price Cuts on Obesity Drugs
(Bloomberg) -- Novo Nordisk A/S and Eli Lilly & Co. shares fell Tuesday after US President Joe Biden demanded price cuts on their blockbuster weight-loss and diabetes drugs. Most Read from BloombergDemocrats Weigh Mid-July Vote to Formally Tap Biden as NomineePowerful Hurricane Beryl Aims at Jamaica After Grenada StrikeTrump Immunity Ruling Means Any Trial Before Election Unlikely‘Upflation’ Is the New Retail Trend Driving Up Prices for US ConsumersBonds Get Respite Amid Powell’s Disinflation Vi
